Cancer Vaccines

Peptide-Based Melanoma Vaccine Tested for Immunogenicity in Melanoma Patients

Published in Vaccine Weekly, September 11th, 1995

'Self' peptide-based vaccines specific for melanoma show immunogenic potential when co-stimulated with a synthetic peptide coding for the MAGE-1 gene.

Research presented at the 1994 International Symposium on Cancer Vaccines (H. Bueler et al.) suggested that enhanced tumor antigen presentation and/or T-cell stimulation were potential major pathways involved in the induction of systemic anti-tumor immunity. Accordingly, in situations with known tumor antigens, it could be feasible to generate efficient antitumor vaccines by introducing relevant antigens into host antigen presenting cells (APCs).

Bijay Mukherji et al. hypothesized that cultured...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry